Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

NCT04268888 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

SUSPENDED

Status

522

Enrollment

OTHER

Sponsor class

Stopped Analysis meant the study should close to recruitment

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Nivolumab and TACE/TAE
PROCEDURE: TACE/TAE

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust